Published in Metabolism on April 27, 2010
Proteome and computational analyses reveal new insights into the mechanisms of hepatitis C virus-mediated liver disease posttransplantation. Hepatology (2012) 1.82
Plasma metabolomic profiles enhance precision medicine for volunteers of normal health. Proc Natl Acad Sci U S A (2015) 1.41
The metabolomic window into hepatobiliary disease. J Hepatol (2013) 1.24
OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin. Proc Natl Acad Sci U S A (2014) 1.24
Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression. Curr Opin Gastroenterol (2012) 1.17
Obesity-dependent metabolic signatures associated with nonalcoholic fatty liver disease progression. J Proteome Res (2012) 1.14
Plasma metabolomics identifies lipid abnormalities linked to markers of inflammation, microbial translocation, and hepatic function in HIV patients receiving protease inhibitors. BMC Infect Dis (2013) 1.10
Dietary supplementation with methyl donors reduces fatty liver and modifies the fatty acid synthase DNA methylation profile in rats fed an obesogenic diet. Genes Nutr (2012) 1.09
Decreased hepatotoxic bile acid composition and altered synthesis in progressive human nonalcoholic fatty liver disease. Toxicol Appl Pharmacol (2013) 1.08
Metabolomic analysis of the effects of polychlorinated biphenyls in nonalcoholic fatty liver disease. J Proteome Res (2012) 1.06
Review: toxicometabolomics. J Appl Toxicol (2013) 1.03
Clinical and Metabolic Characterization of Lean Caucasian Subjects With Non-alcoholic Fatty Liver. Am J Gastroenterol (2016) 1.01
Clinical metabolomics paves the way towards future healthcare strategies. Br J Clin Pharmacol (2013) 0.95
Adipose Tissue Dysfunction and Altered Systemic Amino Acid Metabolism Are Associated with Non-Alcoholic Fatty Liver Disease. PLoS One (2015) 0.95
Branched chain amino acid metabolism profiles in progressive human nonalcoholic fatty liver disease. Amino Acids (2014) 0.93
Nonalcoholic Fatty liver disease, diabetes mellitus and cardiovascular disease: newer data. Int J Endocrinol (2013) 0.93
Altered Bile Acid Metabolome in Patients with Nonalcoholic Steatohepatitis. Dig Dis Sci (2015) 0.92
A (1)H NMR-Based Metabonomic Investigation of Time-Related Metabolic Trajectories of the Plasma, Urine and Liver Extracts of Hyperlipidemic Hamsters. PLoS One (2013) 0.91
Docosahexaenoic acid in plasma phosphatidylcholine may be a potential marker for in vivo phosphatidylethanolamine N-methyltransferase activity in humans. Am J Clin Nutr (2011) 0.91
Serum metabolomic profiling in acute alcoholic hepatitis identifies multiple dysregulated pathways. PLoS One (2014) 0.89
Noninvasive Diagnosis of NASH and Liver Fibrosis Within the Spectrum of NAFLD. Gastroenterol Hepatol (N Y) (2012) 0.87
TGF-β-SMAD3 signaling mediates hepatic bile acid and phospholipid metabolism following lithocholic acid-induced liver injury. J Lipid Res (2012) 0.87
Elevated hepatic fatty acid oxidation, high plasma fibroblast growth factor 21, and fasting bile acids in nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol (2011) 0.87
Metabolomic Endotype of Asthma. J Immunol (2015) 0.85
Serum metabolomic profile and potential biomarkers for severity of fibrosis in nonalcoholic fatty liver disease. J Gastroenterol (2013) 0.85
The gut microbiota modulates host amino acid and glutathione metabolism in mice. Mol Syst Biol (2015) 0.85
Metabolomics of oxidative stress in recent studies of endogenous and exogenously administered intermediate metabolites. Int J Mol Sci (2011) 0.84
Biomarkers in nonalcoholic fatty liver disease. Can J Gastroenterol Hepatol (2014) 0.84
Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research. Prog Lipid Res (2015) 0.84
A metabolomic analysis of omega-3 fatty acid-mediated attenuation of western diet-induced nonalcoholic steatohepatitis in LDLR-/- mice. PLoS One (2013) 0.83
Diagnosing fatty liver disease: a comparative evaluation of metabolic markers, phenotypes, genotypes and established biomarkers. PLoS One (2013) 0.82
Plasma levels of homocysteine and cysteine increased in pediatric NAFLD and strongly correlated with severity of liver damage. Int J Mol Sci (2014) 0.82
Gender Differences in Bile Acids and Microbiota in Relationship with Gender Dissimilarity in Steatosis Induced by Diet and FXR Inactivation. Sci Rep (2017) 0.80
Metabolic profiling of fatty liver in young and middle-aged adults - cross-sectional and prospective analyses of the Young Finns Study. Hepatology (2016) 0.80
Characterizing Blood Metabolomics Profiles Associated with Self-Reported Food Intakes in Female Twins. PLoS One (2016) 0.80
Metabolomic Study on Idiosyncratic Liver Injury Induced by Different Extracts of Polygonum multiflorum in Rats Integrated with Pattern Recognition and Enriched Pathways Analysis. Front Pharmacol (2016) 0.80
Amino Acid Metabolism is Altered in Adolescents with Nonalcoholic Fatty Liver Disease-An Untargeted, High Resolution Metabolomics Study. J Pediatr (2016) 0.79
Association of homocysteine level with biopsy-proven non-alcoholic fatty liver disease: a meta-analysis. J Clin Biochem Nutr (2015) 0.79
Blood transcriptomics and metabolomics for personalized medicine. Comput Struct Biotechnol J (2015) 0.79
Alterations of the gut microbiome and metabolome in alcoholic liver disease. World J Gastrointest Pathophysiol (2014) 0.79
Metabolomic signatures in lipid-loaded HepaRGs reveal pathways involved in steatotic progression. Obesity (Silver Spring) (2013) 0.79
Metabolomic analysis of human cirrhosis, hepatocellular carcinoma, non-alcoholic fatty liver disease and non-alcoholic steatohepatitis diseases. Gastroenterol Hepatol Bed Bench (2016) 0.78
Personal model-assisted identification of NAD(+) and glutathione metabolism as intervention target in NAFLD. Mol Syst Biol (2017) 0.78
Urine and serum metabolomic profiling reveals that bile acids and carnitine may be potential biomarkers of primary biliary cirrhosis. Int J Mol Med (2015) 0.77
Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanism and Application of Metabolomics. Int J Mol Sci (2016) 0.77
Simple steatosis sensitizes cholestatic rats to liver injury and dysregulates bile salt synthesis and transport. Sci Rep (2016) 0.76
Cysteine aggravates palmitate-induced cell death in hepatocytes. Life Sci (2011) 0.76
Bile Acids and Dysbiosis in Non-Alcoholic Fatty Liver Disease. PLoS One (2016) 0.76
Plasma metabolomic analysis of human hepatocellular carcinoma: Diagnostic and therapeutic study. Oncotarget (2016) 0.75
High-Resolution Metabolomics: Review of the Field and Implications for Nursing Science and the Study of Preterm Birth. Biol Res Nurs (2015) 0.75
Clinical Study of Serum Homocysteine and Non-Alcoholic Fatty Liver Disease in Euglycemic Patients. Med Sci Monit (2016) 0.75
Plasma cathepsin D correlates with histological classifications of fatty liver disease in adults and responds to intervention. Sci Rep (2016) 0.75
Gut Microbiota and Complications of Liver Disease. Gastroenterol Clin North Am (2017) 0.75
Metabonomic window into hepatitis B virus-related hepatic diseases. World J Hepatol (2016) 0.75
The Wide and Complex Field of NAFLD Biomarker Research: Trends. ISRN Hepatol (2014) 0.75
Non-Alcoholic Fatty Liver Disease: Current Perspectives and Future Direction in Disease pathogenesis, Treatment and Diagnosis. Med Chem (Los Angeles) (2012) 0.75
Low levels of IgM antibodies recognizing oxidation-specific epitopes are associated with human non-alcoholic fatty liver disease. BMC Med (2016) 0.75
The intrahepatic expression levels of bile acid transporters are inversely correlated with the histological progression of nonalcoholic fatty liver disease. J Gastroenterol (2015) 0.75
Building a genetic risk model for bipolar disorder from genome-wide association data with random forest algorithm. Sci Rep (2017) 0.75
Liver specific expression of Cu/ZnSOD extends the lifespan of Sod1 null mice. Mech Ageing Dev (2016) 0.75
Urinary Metabolomics in Pediatric Obesity and NAFLD Identifies Metabolic Pathways/Metabolites Related to Dietary Habits and Gut-Liver Axis Perturbations. Nutrients (2017) 0.75
Identification of the plasma metabolomics as early diagnostic markers between biliary atresia and neonatal hepatitis syndrome. PLoS One (2014) 0.75
Unravelling the metabolic impact of SBS-associated microbial dysbiosis: Insights from the piglet short bowel syndrome model. Sci Rep (2017) 0.75
Metabolomic profiling distinction of human nonalcoholic fatty liver disease progression from a common rat model. Obesity (Silver Spring) (2017) 0.75
Serum metabolomic profiling highlights pathways associated with liver fat content in a general population sample. Eur J Clin Nutr (2017) 0.75
Metabolomics study of the therapeutic mechanism of Schisandra Chinensis lignans in diet-induced hyperlipidemia mice. Lipids Health Dis (2017) 0.75
Protein tolerance to standard and high protein meals in patients with liver cirrhosis. World J Hepatol (2017) 0.75
A Branched-Chain Amino Acid-Related Metabolic Signature Characterizes Obese Adolescents with Non-Alcoholic Fatty Liver Disease. Nutrients (2017) 0.75
Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia (1985) 109.13
Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (2005) 29.57
Nonalcoholic fatty liver disease. N Engl J Med (2002) 22.41
A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab (2009) 11.46
Molecular mediators of hepatic steatosis and liver injury. J Clin Invest (2004) 9.40
Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology (2001) 8.09
Hepatic insulin resistance directly promotes formation of cholesterol gallstones. Nat Med (2008) 3.66
A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology (2007) 3.65
Endocrine functions of bile acids. EMBO J (2006) 3.03
Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia (2005) 2.67
Insulin resistance of protein metabolism in type 2 diabetes. Diabetes (2007) 2.29
The central role of glutathione in the pathophysiology of human diseases. Arch Physiol Biochem (2007) 2.12
Metabolomics: current technologies and future trends. Proteomics (2006) 1.98
Metabolomics in human nutrition: opportunities and challenges. Am J Clin Nutr (2005) 1.85
Current progress in computational metabolomics. Brief Bioinform (2007) 1.70
Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clin Sci (Lond) (2008) 1.59
Metabolic disturbances in non-alcoholic fatty liver disease. Clin Sci (Lond) (2009) 1.52
Determinants of whole-body protein metabolism in subjects with and without type 2 diabetes. Diabetes Care (2007) 1.45
Bile acids and metabolic regulation: mechanisms and clinical responses to bile acid sequestration. Diabetes Care (2009) 1.19
Elevations of plasma methylarginines in obesity and ageing are related to insulin sensitivity and rates of protein turnover. Diabetologia (2005) 1.19
Evidence for accelerated rates of glutathione utilization and glutathione depletion in adolescents with poorly controlled type 1 diabetes. Diabetes (2005) 1.07
Serum bile acids in hepatobiliary disease. Gut (1978) 1.06
Endocrine and paracrine role of bile acids. World J Gastroenterol (2008) 1.02
Insulin is a dominant suppressor of sterol 12 alpha-hydroxylase P450 (CYP8B) expression in rat liver: possible role of insulin in circadian rhythm of CYP8B. J Biochem (2000) 0.99
Plasma total homocysteine quantification: an improvement of the classical high-performance liquid chromatographic method with fluorescence detection of the thiol-SBD derivatives. J Chromatogr B Analyt Technol Biomed Life Sci (2002) 0.98
Serum bile acids in patients with hyperlipidaemia. J Clin Pathol (1978) 0.95
Glycine and urea kinetics in nonalcoholic steatohepatitis in human: effect of intralipid infusion. Am J Physiol Gastrointest Liver Physiol (2009) 0.95
Bile acid pool changes and regulation of cholate synthesis in experimental diabetes. Biochim Biophys Acta (1978) 0.91
Significance of plasma glutathione determination in patients with alcoholic and non-alcoholic liver disease. J Gastroenterol Hepatol (1992) 0.91
Hepatic glutathione content in patients with alcoholic and non alcoholic liver diseases. Life Sci (1988) 0.90
Bile acids and insulin resistance: implications for treating nonalcoholic fatty liver disease. J Dig Dis (2009) 0.88
Altered bile acid metabolism in alloxan diabetic rats. Jpn J Pharmacol (1979) 0.88
Fatty acids, insulin resistance, and protein metabolism. J Clin Endocrinol Metab (2009) 0.86
Clearance tests of liver function. Med Clin North Am (1979) 0.80
Insulin and cholesterol gallstones: new insights for a complex pathogenic relationship. Hepatology (2008) 0.80
Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (2005) 29.57
Alcoholic liver disease. Hepatology (2010) 5.04
Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology (2009) 4.82
In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology (2006) 4.60
The key role of anaplerosis and cataplerosis for citric acid cycle function. J Biol Chem (2002) 4.20
Analysis of the adult human plasma metabolome. Pharmacogenomics (2008) 3.74
Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology (2007) 3.58
Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med (2002) 3.49
Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology (2005) 3.44
Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology (2010) 2.86
Glyceroneogenesis and the triglyceride/fatty acid cycle. J Biol Chem (2003) 2.60
Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease. J Hepatol (2010) 2.42
Ascitic fluid lactoferrin for diagnosis of spontaneous bacterial peritonitis. Gastroenterology (2008) 2.23
Afternoon colonoscopies have higher failure rates than morning colonoscopies. Am J Gastroenterol (2006) 2.21
Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol (2009) 2.16
Untargeted metabolomic profiling as an evaluative tool of fenofibrate-induced toxicology in Fischer 344 male rats. Toxicol Pathol (2009) 2.16
Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis. J Clin Gastroenterol (2015) 2.11
Renin-angiotensin system and fibrosis in non-alcoholic fatty liver disease. Liver Int (2014) 2.05
Alcoholic liver disease. Am J Gastroenterol (2009) 2.02
Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol (2004) 1.95
Overexpression of the cytosolic form of phosphoenolpyruvate carboxykinase (GTP) in skeletal muscle repatterns energy metabolism in the mouse. J Biol Chem (2007) 1.85
Factors that control the tissue-specific transcription of the gene for phosphoenolpyruvate carboxykinase-C. Crit Rev Biochem Mol Biol (2005) 1.85
Regulation of hepatic gluconeogenesis by an ER-bound transcription factor, CREBH. Cell Metab (2010) 1.80
Smoking and increased severity of hepatic fibrosis in primary biliary cirrhosis: A cross validated retrospective assessment. Hepatology (2006) 1.79
The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation. Liver Transpl (2008) 1.75
Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J Hepatol (2012) 1.70
Improving compliance with postpolypectomy surveillance guidelines: an interventional study using a continuous quality improvement initiative. Gastrointest Endosc (2006) 1.59
Nanoparticles of compacted DNA transfect postmitotic cells. J Biol Chem (2003) 1.58
What is the metabolic role of phosphoenolpyruvate carboxykinase? J Biol Chem (2009) 1.57
Progressive primary sclerosing cholangitis requiring liver transplantation is associated with reduced need for colectomy in patients with ulcerative colitis. Clin Gastroenterol Hepatol (2012) 1.56
Resurgence of serine: an often neglected but indispensable amino Acid. J Biol Chem (2012) 1.51
Glyceroneogenesis is the dominant pathway for triglyceride glycerol synthesis in vivo in the rat. J Biol Chem (2008) 1.49
Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology (2011) 1.47
Biomarkers for type 2 diabetes and impaired fasting glucose using a nontargeted metabolomics approach. Diabetes (2013) 1.44
Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study. Hepatology (2009) 1.37
A sister group contrast using untargeted global metabolomic analysis delineates the biochemical regulation underlying desiccation tolerance in Sporobolus stapfianus. Plant Cell (2011) 1.37
Pathogenesis of non-alcoholic steatohepatitis: human data. Clin Liver Dis (2007) 1.33
Pathologic features associated with fibrosis in nonalcoholic fatty liver disease. Hum Pathol (2004) 1.32
Diabetes mellitus, obesity, and hepatic steatosis. Semin Gastrointest Dis (2002) 1.27
Phosphoenolpyruvate carboxykinase and the critical role of cataplerosis in the control of hepatic metabolism. Nutr Metab (Lond) (2005) 1.25
A mutation in the peroxisome proliferator-activated receptor gamma-binding site in the gene for the cytosolic form of phosphoenolpyruvate carboxykinase reduces adipose tissue size and fat content in mice. Proc Natl Acad Sci U S A (2002) 1.25
Malnutrition in cirrhosis: contribution and consequences of sarcopenia on metabolic and clinical responses. Clin Liver Dis (2012) 1.24
Obesity and non-alcoholic fatty liver disease in chronic hepatitis C. J Clin Gastroenterol (2004) 1.23
Urine metabolomic analysis identifies potential biomarkers and pathogenic pathways in kidney cancer. OMICS (2011) 1.23
Posttransplant metabolic syndrome: an epidemic waiting to happen. Liver Transpl (2009) 1.22
Role of ceramides in nonalcoholic fatty liver disease. Trends Endocrinol Metab (2012) 1.20
Metabolic response of mice to a postnatal ablation of CCAAT/enhancer-binding protein alpha. J Biol Chem (2005) 1.19
Reassessing triglyceride synthesis in adipose tissue. Trends Endocrinol Metab (2008) 1.18
SREBP-1c and Sp1 interact to regulate transcription of the gene for phosphoenolpyruvate carboxykinase (GTP) in the liver. J Biol Chem (2004) 1.18
Measuring protein synthesis using metabolic ²H labeling, high-resolution mass spectrometry, and an algorithm. Anal Biochem (2011) 1.16
Quantification of ceramide species in biological samples by liquid chromatography electrospray ionization tandem mass spectrometry. Anal Biochem (2010) 1.15
Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: new evidence on the potential therapeutic mechanism. Hepatology (2012) 1.14
Urinary acylcarnitines are altered in human kidney cancer. Int J Cancer (2011) 1.14
Skeletal muscle atrophy is associated with an increased expression of myostatin and impaired satellite cell function in the portacaval anastamosis rat. Am J Physiol Gastrointest Liver Physiol (2004) 1.13
Aspects of the control of phosphoenolpyruvate carboxykinase gene transcription. J Biol Chem (2009) 1.13
Hyperammonemia-mediated autophagy in skeletal muscle contributes to sarcopenia of cirrhosis. Am J Physiol Endocrinol Metab (2012) 1.12
Activation of SIRT1 by resveratrol represses transcription of the gene for the cytosolic form of phosphoenolpyruvate carboxykinase (GTP) by deacetylating hepatic nuclear factor 4alpha. J Biol Chem (2009) 1.12
Steatohepatitis in obese individuals. Best Pract Res Clin Gastroenterol (2002) 1.12
Hyperammonemia in cirrhosis induces transcriptional regulation of myostatin by an NF-κB-mediated mechanism. Proc Natl Acad Sci U S A (2013) 1.11
Role of fresh frozen plasma infusion in correction of coagulopathy of chronic liver disease: a dual phase study. Am J Gastroenterol (2003) 1.11
Presence of sarcopenia (muscle wasting) in patients with nonalcoholic steatohepatitis. Hepatology (2014) 1.08
Glucocorticoids regulate transcription of the gene for phosphoenolpyruvate carboxykinase in the liver via an extended glucocorticoid regulatory unit. J Biol Chem (2005) 1.05
Perturbation of bile acid homeostasis is an early pathogenesis event of drug induced liver injury in rats. Toxicol Appl Pharmacol (2013) 1.05
Metabolic and genomic response to dietary isocaloric protein restriction in the rat. J Biol Chem (2010) 1.05
Plasma proteome dynamics: analysis of lipoproteins and acute phase response proteins with 2H2O metabolic labeling. Mol Cell Proteomics (2012) 1.05
Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease. J Crohns Colitis (2012) 1.04
Diagnosis and management of alcoholic liver disease. J Dig Dis (2011) 1.03
Gender differences in the regulation of amino acid metabolism. J Appl Physiol (1985) (2003) 1.03
Altered expression of genes regulating skeletal muscle mass in the portacaval anastomosis rat. Am J Physiol Gastrointest Liver Physiol (2006) 1.02
Reversal of sarcopenia predicts survival after a transjugular intrahepatic portosystemic stent. Eur J Gastroenterol Hepatol (2013) 1.01
Hypovitaminosis D is associated with increased whole body fat mass and greater severity of non-alcoholic fatty liver disease. Liver Int (2013) 1.00
Metabolomic profiling reveals biochemical pathways and biomarkers associated with pathogenesis in cystic fibrosis cells. J Biol Chem (2010) 1.00
Metabolic programming: fetal origins of obesity and metabolic syndrome in the adult. Am J Physiol Endocrinol Metab (2006) 0.99
Sarcopenia associated with portosystemic shunting is reversed by follistatin. J Hepatol (2010) 0.99
Metabolomic profiling in Selaginella lepidophylla at various hydration states provides new insights into the mechanistic basis of desiccation tolerance. Mol Plant (2012) 0.97
Metabolic perturbance in autism spectrum disorders: a metabolomics study. J Proteome Res (2012) 0.97
The relevance of liver histology to predicting clinically meaningful outcomes in nonalcoholic steatohepatitis. Clin Liver Dis (2012) 0.97
Comparative metabolic profiling between desiccation-sensitive and desiccation-tolerant species of Selaginella reveals insights into the resurrection trait. Plant J (2012) 0.97
Short-term exercise reduces markers of hepatocyte apoptosis in nonalcoholic fatty liver disease. J Appl Physiol (1985) (2012) 0.96
Glycine and urea kinetics in nonalcoholic steatohepatitis in human: effect of intralipid infusion. Am J Physiol Gastrointest Liver Physiol (2009) 0.95
Methionine and protein metabolism in non-alcoholic steatohepatitis: evidence for lower rate of transmethylation of methionine. Clin Sci (Lond) (2011) 0.94
Prevalence of hypothyroidism in nonalcoholic fatty liver disease. Dig Dis Sci (2011) 0.94
The chloroplast triggers developmental reprogramming when mutS HOMOLOG1 is suppressed in plants. Plant Physiol (2012) 0.93
Increased serum levels of carbohydrate antigen 19-9 and outcomes in primary sclerosing cholangitis patients without cholangiocarcinoma. Dig Dis Sci (2012) 0.92
3-hydroxykynurenine and other Parkinson's disease biomarkers discovered by metabolomic analysis. Mov Disord (2013) 0.92
Enhanced energy metabolism contributes to the extended life span of calorie-restricted Caenorhabditis elegans. J Biol Chem (2012) 0.92
Metabolite profiles correlate closely with neurobehavioral function in experimental spinal cord injury in rats. PLoS One (2012) 0.91